Sun Hee Lee

Sun Hee Lee

Auto-generated profile, based on publicly available information

Sun Hee Lee

Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2009 in Chemical Communications
Verified
Journal Article
Open access
PDF file
Su Ryon ShinSu Ryon Shin
Su Ryon Shin
CLChang Kee Lee
Chang Kee Lee
SLSun Hee Lee
Sun Hee Lee
SKSun I. Kim
Sun I. Kim
GSGeoffrey Spinks
Geoffrey Spinks
SKSeon Kim
Seon Kim
The switching electrochemical property of an SWNT/DNA hybrid can be produced through reversible conformational changes between the closed and open state originating from the pH-responding i-motif DNA which significantly improves its molecular switching and stability by hydrophobic interactions with SWNTs.


1 January 2026 in JCO Oncology Advances
Verified
Journal Article
Open access
LVLuigi Antonio De Vitis
Luigi Antonio De Vitis
MLMelissa Larson
Melissa Larson
HAHunter J. Atkinson
Hunter J. Atkinson
MBMatthew Stephen Block
Matthew Stephen Block
WCWilliam Cliby
William Cliby
AOAnn L. Oberg
Ann L. Oberg
PURPOSE: To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS: This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS: A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION: In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.

28 April 2022 in Journal of Biological Chemistry
Verified
Journal Article
Open access
XMXue Wei Meng
Xue Wei Meng
KPKevin L. Peterson
Kevin L. Peterson
HDHaiming Dai
Haiming Dai
PSPaula Schneider
Paula Schneider
SLSun-Hee Lee
Sun-Hee Lee
SKScott Kaufmann
Scott Kaufmann